Innovent Biologics (HKSE:01801) Current Accrued Expense : HK$0 Mil (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Innovent Biologics Current Accrued Expense?

Innovent Biologics's Current Accrued Expense for the quarter that ended in Jun. 2023 was HK$0 Mil.

Innovent Biologics Current Accrued Expense Historical Data

The historical data trend for Innovent Biologics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics Current Accrued Expense Chart

Innovent Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

Innovent Biologics Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Current Accrued Expense	Get a 7-Day Free Trial										-	-	-	-	-

Innovent Biologics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Innovent Biologics Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovent Biologics (HKSE:01801) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (HKSE:01801) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

IVBXF:USA IVBIY:USA 6IB:Germany

Address

168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.innoventbio.com

Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.

Innovent Biologics (HKSE:01801) Headlines

No Headlines